With over 18 subspecialties and 60+ experts, we can help with even the most difficult cases.
NEWS & EVENTS
FDA Approves First-Ever Drug for a Rare and Aggressive Brain Cancer
Department of Pediatrics originally published in 2023 has lead the U.S. Food and Drug Administration (FDA) to accelerate approval of the drug ONC201 now called dordaviprone for the treatment of diffuse midline glioma (DMG) with an H3 K27M mutation. A rare, aggressive brain tumor that primarily affects children and young adults. This marks the first FDA-approved therapy for this form of cancer.
Study Reveals Mechanisms Behind Common Mutation and Prostate Cancer
Researchers discovered two distinct ways mutation of the FOXA1 gene alters tumor formation and therapy resistance in prostate cancer in mouse models.
From Health Lab: Study Defines Key Driver of Aggressive Ovarian Cancer
A study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential pathway for new treatments.
